Brokerages expect Fate Therapeutics Inc (NASDAQ:FATE) to report sales of $1.02 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Fate Therapeutics’ earnings. The highest sales estimate is $1.03 million and the lowest is $1.00 million. Fate Therapeutics posted sales of $1.03 million during the same quarter last year, which suggests a negative year over year growth rate of 1%. The company is scheduled to report its next quarterly earnings results on Thursday, March 15th.
On average, analysts expect that Fate Therapeutics will report full-year sales of $1.02 million for the current fiscal year, with estimates ranging from $4.00 million to $4.11 million. For the next fiscal year, analysts anticipate that the firm will post sales of $5.66 million per share, with estimates ranging from $4.02 million to $12.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Fate Therapeutics.
FATE has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Fate Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 price target on the stock in a report on Tuesday, January 9th. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Fate Therapeutics in a report on Friday, November 10th. BMO Capital Markets reissued a “buy” rating and issued a $7.00 price target on shares of Fate Therapeutics in a report on Thursday, November 2nd. Raymond James Financial reissued a “buy” rating on shares of Fate Therapeutics in a report on Tuesday, December 12th. Finally, ValuEngine raised shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Fate Therapeutics presently has a consensus rating of “Buy” and an average price target of $7.71.
Institutional investors and hedge funds have recently made changes to their positions in the company. New York State Common Retirement Fund bought a new stake in shares of Fate Therapeutics during the 2nd quarter valued at about $131,000. Rhumbline Advisers bought a new stake in shares of Fate Therapeutics during the 2nd quarter valued at about $133,000. Hochman Cole Investment Advisors Inc. bought a new stake in shares of Fate Therapeutics during the 3rd quarter valued at about $158,000. The Manufacturers Life Insurance Company boosted its stake in shares of Fate Therapeutics by 61.4% during the 4th quarter. The Manufacturers Life Insurance Company now owns 33,337 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 12,686 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. bought a new stake in shares of Fate Therapeutics during the 2nd quarter valued at about $214,000. 50.00% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “$1.02 Million in Sales Expected for Fate Therapeutics Inc (FATE) This Quarter” was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/14/1-02-million-in-sales-expected-for-fate-therapeutics-inc-fate-this-quarter.html.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.